|
1
|
Zhang J, Wang Y, Li D and Jing S: Notch
and TGF-β/Smad3 pathways are involved in the interaction between
cancer cells and cancer-associated fibroblasts in papillary thyroid
carcinoma. Tumour Biol. 35:379–385. 2014.
|
|
2
|
Davies L and Welch HG: Increasing
incidence of thyroid cancer in the United States, 1973–2002. JAMA.
295:2164–2167. 2006.
|
|
3
|
Tavares MR, Toledo SP, Montenegro FL, et
al: Surgical approach to medullary thyroid carcinoma associated
with multiple endocrine neoplasia type 2. Clinics (Sao Paulo).
67(Suppl 1): 149–154. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tavares MR, Michaluart P Jr, Montenegro F,
et al: Skip metastases in medullary thyroid carcinoma: a
single-center experience. Surg Today. 38:499–504. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Machens A, Lorenz K and Dralle H:
Individualization of lymph node dissection in RET (rearranged
during transfection) carriers at risk for medullary thyroid cancer:
value of pre-therapeutic calcitonin levels. Ann Surg. 250:305–310.
2009. View Article : Google Scholar
|
|
6
|
Singal PK, Li T, Kumar D, et al:
Adriamycin-induced heart failure: mechanism and modulation. Mol
Cell Biochem. 207:77–86. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Carvalho C, Santos RX, Cardoso S, et al:
Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem.
16:3267–3285. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Silber JH and Barber G:
Doxorubicin-induced cardiotoxicity. N Engl J Med. 333:1359–1360.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
King PD and Perry MC: Hepatotoxicity of
chemotherapy. Oncologist. 6:162–176. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang S, Konorev EA, Kotamraju S, et al:
Doxorubicin induces apoptosis in normal and tumor cells via
distinctly different mechanisms. Intermediacy of H(2)O(2)- and
p53-dependent pathways. J Biol Chem. 279:25535–25543. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mukhopadhyay P, Rajesh M, Bátkai S, et al:
Role of superoxide, nitric oxide, and peroxynitrite in
doxorubicin-induced cell death in vivo and in vitro. Am J Physiol
Heart Circ Physiol. 296:1466–1483. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Das A, Durrant D, Mitchell C, Mayton E, et
al: Sildenafil increases chemotherapeutic efficacy of doxorubicin
in prostate cancer and ameliorates cardiac dysfunction. Proc Natl
Acad Sci USA. 107:18202–18207. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dayton A, Selvendiran K, Meduru S, Khan M,
et al: Amelioration of doxorubicin-induced cardiotoxicity by an
anticancer-antioxidant dual-function compound, HO-3867. J Pharmacol
Exp Ther. 339:350–357. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen C, Xu W and Wang CM: Combination of
celecoxib and doxorubicin increases growth inhibition and apoptosis
in acute myeloid leukemia cells. Leuk Lymphoma. 54:2517–2522. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ponthan F, Wickström M, Gleissman H, et
al: Celecoxib prevents neuroblastoma tumor development and
potentiates the effect of chemotherapeutic drugs in vitro and in
vivo. Clin Cancer Res. 13:1036–1044. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dai ZJ, Gao J, Li ZF, et al: In vitro and
in vivo antitumor activity of Scutellaria barbate extract on murine
liver cancer. Molecules. 16:4389–4400. 2001.PubMed/NCBI
|
|
18
|
Cohen EE, Rosen LS, Vokes EE, et al:
Axitinib is an active treatment for all histologic subtypes of
advanced thyroid cancer: results from a phase II study. J Clin
Oncol. 26:4708–4713. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Salgia R, Sherman S, Hong DS, Ng CS, et
al: A phase I study of XL184, a RET, VEGFR2, and MET kinase
inhibitor, in patients (pts) with advanced malignancies, including
pts with medullary thyroid cancer (MTC). J Clin Oncol. 26(15S):
35222008.
|
|
20
|
Schlumberger MJ, Elisei R, Bastholt L, et
al: Phase II study of safety and efficacy of motesanib in patients
with progressive or symptomatic, advanced or metastatic medullary
thyroid cancer. J Clin Oncol. 27:3794–3801. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wells SA Jr, Gosnell JE, Gagel RF, et al:
Vandetanib for the treatment of patients with locally advanced or
metastatic hereditary medullary thyroid cancer. J Clin Oncol.
28:767–772. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zatelli MC, Luchin A, Piccin D, et al:
Cyclooxygenase-2 Inhibitors Reverse Chemoresistance Phenotype in
Medullary Thyroid Carcinoma by a Permeability Glycoprotein-Mediated
Mechanism. J Clin Endocrinol Metab. 90:5754–5760. 2005. View Article : Google Scholar
|
|
23
|
Vivaldi A, Ciampi R, Tacito A, et al:
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the
chemotherapic effect of vinorelbine in the medullary thyroid cancer
TT cell line. Mol Cell Endocrinol. 355:41–48. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hoff AO and Hoff PM: Medullary thyroid
carcinoma. Hematol Oncol Clin North Am. 21:475–488. 2008.
View Article : Google Scholar
|
|
25
|
Massart C, Gibassier J, Lucas C, et al:
Expression of the MDR1 gene in five human cell lines of medullary
thyroid cancer and reversion of the resistance to doxorubicine by
ciclosporin A and verapamil. Bull Cancer. 83:39–45. 1996.(In
French).
|
|
26
|
Breier A, Barancík M, Sulová Z and Uhrík
B: P-glycoprotein - implications of metabolism of neoplastic cells
and cancer therapy. Curr Cancer Drug Targets. 5:457–468. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Doyle L and Ross DD: Multidrug resistance
mediated by the breast cancer resistance protein BCRP (ABCG2).
Oncogene. 22:7340–7358. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Johnstone RW, Ruefli AA and Smyth MJ:
Multiple physiological functions for multidrug transporter
P-glycoprotein? Trends Biochem Sci. 25:1–6. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Patel VA, Dunn MJ and Sorokin A:
Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. J Biol
Chem. 277:38915–38920. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jendrossek V: Targeting apoptosis pathways
by Celecoxib in cancer. Cancer Lett. 322:313–324. 2013. View Article : Google Scholar
|
